{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:29:41Z","timestamp":1792146581064,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04575-0","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:47:35Z","timestamp":1760770055000},"page":"4341-4356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["METTL3\/IGF2BP3 axis promotes gemcitabine resistance of pancreatic cancer cells through regulating USP33-mediated PAK1 deubiquitination and degradation"],"prefix":"10.1007","volume":"399","author":[{"given":"Ling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolan","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"4575_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H (2022) The role of m6A RNA methylation in cancer metabolism. Mol Cancer 21:14","journal-title":"Mol Cancer"},{"key":"4575_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36246-0","volume":"14","author":"WC Chan","year":"2023","unstructured":"Chan WC, Liu X, Magin RS et al (2023) Accelerating inhibitor discovery for deubiquitinating enzymes. Nat Commun 14:686","journal-title":"Nat Commun"},{"key":"4575_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2023.194979","volume":"1866","author":"G Dagar","year":"2023","unstructured":"Dagar G, Kumar R, Yadav KK, Singh M, Pandita TK (2023) Ubiquitination and deubiquitination: implications on cancer therapy. Biochimica et Biophysica Acta (BBA) 1866:194979","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"4575_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard RB (2021) The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ 28:423\u2013426","journal-title":"Cell Death Differ"},{"key":"4575_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41418-019-0473-8","volume":"27","author":"F Guo","year":"2020","unstructured":"Guo F, Zhang C, Wang F et al (2020) Deubiquitinating enzyme USP33 restrains docetaxel-induced apoptosis via stabilising the phosphatase DUSP1 in prostate cancer. Cell Death Differ 27:1938\u20131951","journal-title":"Cell Death Differ"},{"key":"4575_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.962204","volume":"12","author":"Z Guo","year":"2022","unstructured":"Guo Z, Zhang X, Lin C et al (2022) METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Front Oncol 12:962204","journal-title":"Front Oncol"},{"key":"4575_CR7","first-page":"1","volume":"50","author":"H Han","year":"2021","unstructured":"Han H, Feng F, Li H (2021) Research advances on epigenetics and cancer metabolism. Zhejiang Da Xue Xue Bao Yi Xue Ban 50:1\u201316","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"4575_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.5582\/ddt.2019.01068","volume":"13","author":"R Hennig","year":"2019","unstructured":"Hennig R, Albawardi A, Almarzooqi S et al (2019) 1,2,3-triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice. Drug Discov Ther 13:248\u2013255","journal-title":"Drug Discov Ther"},{"key":"4575_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/annonc\/mdw184","volume":"27","author":"S Jagadeeshan","year":"2016","unstructured":"Jagadeeshan S, Subramanian A, Tentu S et al (2016) P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer. Ann Oncol 27:1546\u20131556","journal-title":"Ann Oncol"},{"key":"4575_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, Fu Y, Zhao X et al (2011) N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 7:885\u2013887","journal-title":"Nat Chem Biol"},{"key":"4575_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2174\/0115701646317271240821071544","volume":"21","author":"F Jiana","year":"2024","unstructured":"Jiana F, Jingru H, Jiazhong Z, Lin C, Jin D (2024) Comprehensive analysis of tertiary lymphoid structures in pancreatic cancer: molecular characteristics and prognostic implications. Curr Proteomics 21:230\u2013250","journal-title":"Curr Proteomics"},{"key":"4575_CR12","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","volume":"25","author":"SD Kamath","year":"2020","unstructured":"Kamath SD, Kalyan A, Kircher S et al (2020) Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist 25:e808\u2013e815","journal-title":"Oncologist"},{"key":"4575_CR13","doi-asserted-by":"crossref","unstructured":"Kichina JV, Maslov A, Kandel ES (2023) PAK1 and therapy resistance in melanoma. Cells 12:2373","DOI":"10.3390\/cells12192373"},{"key":"4575_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein AP (2021) Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol 18:493\u2013502","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4575_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10735-011-9363-1","volume":"42","author":"A Konieczna","year":"2011","unstructured":"Konieczna A, Erd\u00f6sov\u00e1 B, Lichnovsk\u00e1 R et al (2011) Differential expression of ABC transporters (MDR1, MRP1, BCRP) in developing human embryos. J Mol Histol 42:567\u2013574","journal-title":"J Mol Histol"},{"key":"4575_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05715-1","volume":"14","author":"C Lin","year":"2023","unstructured":"Lin C, Li T, Wang Y et al (2023) METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation. Cell Death Dis 14:221","journal-title":"Cell Death Dis"},{"key":"4575_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D et al (2014) A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol 10:93\u201395","journal-title":"Nat Chem Biol"},{"key":"4575_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05871-4","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Xu J, Shen B, Xu J, Jiang J (2023) Usp33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2\/TGF\u03b2 signaling pathway. Cell Death Dis 14:362","journal-title":"Cell Death Dis"},{"key":"4575_CR19","doi-asserted-by":"publisher","first-page":"1911592","DOI":"10.1155\/2022\/1911592","volume":"2022","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zhou S, Cheng G et al (2022) CircLMTK2 silencing attenuates gemcitabine resistance in pancreatic cancer by sponging miR-485-5p and to target PAK1. J Oncol 2022:1911592","journal-title":"J Oncol"},{"key":"4575_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02110-4","volume":"16","author":"C Lu","year":"2025","unstructured":"Lu C, Su Y, Xu Y et al (2025) A novel PAK1\/TCF1 regulatory axis promotes non-small cell lung cancer progression. Discover Oncol 16:364","journal-title":"Discover Oncol"},{"key":"4575_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.molcel.2016.09.014","volume":"64","author":"F Ohtake","year":"2016","unstructured":"Ohtake F, Saeki Y, Ishido S, Kanno J, Tanaka K (2016) The K48\u2013K63 branched ubiquitin chain regulates NF-\u03baB signaling. Mol Cell 64:251\u2013266","journal-title":"Mol Cell"},{"key":"4575_CR22","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/jca.14922","volume":"7","author":"K Polireddy","year":"2016","unstructured":"Polireddy K, Chen Q (2016) Cancer of the pancreas: molecular pathways and current advancement in treatment. J Cancer 7:1497\u20131514","journal-title":"J Cancer"},{"key":"4575_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrc3645","volume":"14","author":"M Radu","year":"2014","unstructured":"Radu M, Semenova G, Kosoff R, Chernoff J (2014) PAK signalling during the development and progression of cancer. Nat Rev Cancer 14:13\u201325","journal-title":"Nat Rev Cancer"},{"key":"4575_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08292-1","author":"D Ramai","year":"2024","unstructured":"Ramai D, Smith ER, Wang Y et al (2024) Epidemiology and socioeconomic impact of pancreatic cancer: an analysis of the Global Burden of Disease study 1990\u20132019. Dig Dis Sci. https:\/\/doi.org\/10.1007\/s10620-024-08292-1","journal-title":"Dig Dis Sci"},{"key":"4575_CR25","doi-asserted-by":"crossref","unstructured":"Ramos-Alvarez I, Jensen RT (2025) The important role of p21-activated kinases in pancreatic exocrine function. Biological (Basel) 14:113","DOI":"10.3390\/biology14020113"},{"key":"4575_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.hoc.2022.07.006","volume":"36","author":"M Rehman","year":"2022","unstructured":"Rehman M, Khaled A, Noel M (2022) Cytotoxic chemotherapy in advanced pancreatic cancer. Hematol Oncol Clin North Am 36:1011\u20131018","journal-title":"Hematol Oncol Clin North Am"},{"key":"4575_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree IA, Evans ME, Pan T, He C (2017) Dynamic RNA modifications in gene expression regulation. Cell 169:1187\u20131200","journal-title":"Cell"},{"key":"4575_CR28","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"4575_CR29","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1083\/jcb.201902074","volume":"218","author":"L Song","year":"2019","unstructured":"Song L, Luo ZQ (2019) Post-translational regulation of ubiquitin signaling. J Cell Biol 218:1776\u20131786","journal-title":"J Cell Biol"},{"key":"4575_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-020-00245-6","author":"M Tracz","year":"2021","unstructured":"Tracz M, Bialek W (2021) Beyond K48 and K63: non-canonical protein ubiquitination. Cell Mol Biol Lett. https:\/\/doi.org\/10.1186\/s11658-020-00245-6","journal-title":"Cell Mol Biol Lett"},{"key":"4575_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A et al (2014) N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505:117\u2013120","journal-title":"Nature"},{"key":"4575_CR32","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, Zhao BS, Roundtree IA et al (2015) N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161:1388\u20131399","journal-title":"Cell"},{"key":"4575_CR33","doi-asserted-by":"publisher","first-page":"G632","DOI":"10.1152\/ajpgi.00344.2018","volume":"316","author":"K Wang","year":"2019","unstructured":"Wang K, Baldwin GS, Nikfarjam M, He H (2019) Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 316:G632\u2013G640","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4575_CR34","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","volume":"163","author":"LD Wood","year":"2022","unstructured":"Wood LD, Canto MI, Jaffee EM, Simeone DM (2022) Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163:386-402.e381","journal-title":"Gastroenterology"},{"key":"4575_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114118","volume":"230","author":"P Xu","year":"2022","unstructured":"Xu P, Ge R (2022) Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. Eur J Med Chem 230:114118","journal-title":"Eur J Med Chem"},{"key":"4575_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218035","author":"Y Yang","year":"2020","unstructured":"Yang Y, Huynh N, Dumesny C et al (2020) Cannabinoids inhibited pancreatic cancer via P-21 activated kinase 1 mediated pathway. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21218035","journal-title":"Int J Mol Sci"},{"key":"4575_CR37","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.7150\/thno.46913","volume":"10","author":"D Yao","year":"2020","unstructured":"Yao D, Li C, Rajoka MSR et al (2020) P21-activated kinase 1: emerging biological functions and potential therapeutic targets in cancer. Theranostics 10:9741\u20139766","journal-title":"Theranostics"},{"key":"4575_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-016-2057-z","volume":"16","author":"D Yeo","year":"2016","unstructured":"Yeo D, He H, Patel O et al (2016) FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer 16:24","journal-title":"BMC Cancer"},{"key":"4575_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184504","author":"S Zeng","year":"2019","unstructured":"Zeng S, P\u00f6ttler M, Lan B et al (2019) Chemoresistance in pancreatic cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20184504","journal-title":"Int J Mol Sci"},{"key":"4575_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W, Li Y, Weng H (2020) Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol 13:117","journal-title":"J Hematol Oncol"},{"key":"4575_CR41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/OTT.S229055","volume":"13","author":"S Zhang","year":"2020","unstructured":"Zhang S, Shi W, Hu W et al (2020) DEP domain-containing protein 1B (DEPDC1B) promotes migration and invasion in pancreatic cancer through the Rac1\/PAK1-LIMK1-Cofilin1 signaling pathway. Onco Targets Ther 13:1481\u20131496","journal-title":"Onco Targets Ther"},{"key":"4575_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-00872-8","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shi Y, Shen H, Xie W (2020) M(6)a-binding proteins: the emerging crucial performers in epigenetics. J Hematol Oncol 13:35","journal-title":"J Hematol Oncol"},{"key":"4575_CR43","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/cbin.12024","volume":"47","author":"B Zhong","year":"2023","unstructured":"Zhong B, Zhu Q, Wang L et al (2023) USP33 enhances cell survival and stemness by deubiquitinating CTNNB1 in BXPC-3 and SW1990 cells. Cell Biol Int 47:1368\u20131380","journal-title":"Cell Biol Int"},{"key":"4575_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/path.4412","volume":"234","author":"W Zhou","year":"2014","unstructured":"Zhou W, Jubb AM, Lyle K et al (2014) PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol 234:502\u2013513","journal-title":"J Pathol"},{"key":"4575_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-023-00499-0","volume":"11","author":"TY Zhu","year":"2023","unstructured":"Zhu TY, Hong LL, Ling ZQ (2023) Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res 11:62","journal-title":"Biomark Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04575-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:00:48Z","timestamp":1772006448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04575-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4575"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04575-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the ethical review committee of Central Hospital of Xianning City, The First Affiliated Hospital, Hubei College of Science and Technology. Written informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients agree to participate in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}